Search

Displaying results 6381 - 6390 of 10000 in total
  1. Drug

    Hydrocortisone cypionate

    go.drugbank.com/drugs/DB14541
    ApprovedVet approvedWithdrawn

  2. Drug

    Hydrocortisone acetate

    go.drugbank.com/drugs/DB14539
    ApprovedInvestigationalVet approved

    Mixtures: Analpram E, Analpram E
  3. Drug

    Hydrocortisone valerate

    go.drugbank.com/drugs/DB14544
    ApprovedVet approved

  4. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.

  5. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    Integrins are important adhesion molecules that regulate tumor and endothelial cell survival, proliferation and migration. The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin ant...

  6. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

  7. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

  8. Drug

    Polyvalent antigen-KLH conjugate vaccine

    go.drugbank.com/drugs/DB17565
    Investigational

    It is under investigation in clinical trial NCT01223235 (Polyvalent Vaccine-klh Conjugate + Opt-821 Given in Combination With Bevacizumab). … Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant

  9. Drug

    Brifentanil

    go.drugbank.com/drugs/DB09172
    ExperimentalIllicit

    Brifentanil (also known as A-3331) is an analog of fentanyl, a potent opioid. This drug is classified as an opioid analgesic and was developed in the early 1990s.

  10. Drug

    MBT-0312

    go.drugbank.com/drugs/DB05880
    Experimental

    MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.